As Lilly gears up for key 2022 launches, Trulicity, Taltz and more drive solid growth

Lilly's diabetes medicine Trulicity, immunology blockbuster Taltz, breast cancer drug Verzenio and migraine prevention medicine Emgality each posted revenue gains of more than 30 percentage points versus the prior quarter, propelling the company to a $6.77 billion quarterly haul. On the flip side, sales for Lilly's insulins Humalog and Humulin, cancer med Alimta and osteoporosis injection Forteo declined amid competitive challenges leading to lower prices.